Dr Julie Fox qualified from the University of Manchester and trained in Genitourinary Medicine at Imperial College London, UK. She leads the HIV clinical trials unit at Guys’ and St Thomas’ NHS Trust and is a Reader in HIV Infection in the School of Immunology & Microbial Sciences at King’s College London. She is a Chief Investigator on national and international multi-centre intervention studies collaborating with NHS and academic partners across the UK, Europe and Sub-Saharan Africa.
Dr Fox’s research focuses on HIV prevention (vaccine and pre-exposure prophylaxis), HIV cure and optimising HIV treatment. She collaborates widely and is a keen proponent of multidisciplinary research. She is a co-founder of the UK HIV cure group Collaborative HIV Eradication of Reservoirs: UK BRC (CHERUB) and leads the international combined HIV adolescent prevention group CHAPS, which is funded by the European and Developing Countries Clinical Trials Partnership (EDCTP) and focuses on HIV prevention in young adults in South Africa, Uganda and Zimbabwe. Furthermore, she is a trial physician in the EDCTP-funded international HIV vaccine and PrEP study PREPVACC, which is taking place in Uganda, South Africa, Tanzania and Mozambique.
Dr Fox has recently been researching SARS-CoV-2 and is leading the EDTP-funded COVAB group, a multidisciplinary research network across UK, Uganda and South Africa that works on evaluating SARS-CoV-2 antibody evolution, developing a SARS-CoV-2 ex vivo challenge model and carrying out public engagement in rural communities (COVAB). She is Chief Investigator of the COV-TT test and treat study and is collecting longitudinal samples from special populations in order to evaluate antibody response to vaccination (COVAB-B). In addition, she co-leads the HIV group in the Oxford COV002 AstraZenica vaccine trial.
